MA
SGMO

MYDA Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

MYDA Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-40,000
Closed -$26.8K – 159
2024
Q1 		$26.8K Buy
+40,000
New +$29K 0.01% 116

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MYDA Advisors's SGMO Position: Q2 2024 in Review

MYDA Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2024, closing a stake of 40,000 shares — an estimated $26.8K sold.

MYDA Advisors first reported a position in SGMO in Q1 2024 and held it in 1 quarter. The position peaked at $26.8K in Q1 2024. 129 funds tracked by Wall St. Rank hold SGMO as of Q2 2024.

  • MYDA Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2024 after selling out during the quarter.
  • MYDA Advisors sold 40,000 SANGAMO THERAPEUTICS INC shares in Q2 2024, an estimated $26.8K.
  • MYDA Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q1 2024 and held it in 1 quarter.
  • MYDA Advisors's SANGAMO THERAPEUTICS INC position peaked at $26.8K in Q1 2024.
  • 129 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2024.

Based on MYDA Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.